Synonym
IST-622; IST622; IST 622;
IUPAC/Chemical Name
10-(((3aS,4R,6S,7R,7aS)-7-(((2R,3R,4S,5S,6R)-3,5-dihydroxy-4-methoxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-methyl-2-phenyltetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-6-yl)oxy)-1-methyl-5,12-dioxo-5,12-dihydrobenzo[h]chromeno[5,4,3-cde]chromen-6-yl 3-ethoxypropanoate
InChi Key
YAZCVTSUQIJVMZ-HDGDFCDYSA-N
InChi Code
InChI=1S/C44H44O16/c1-6-51-18-17-26(45)56-35-23-13-10-14-24(28(23)36-30-29-25(54-41(49)31(30)35)16-15-19(2)27(29)40(48)57-36)55-44-39(60-43-33(47)37(50-5)32(46)20(3)52-43)38-34(21(4)53-44)58-42(59-38)22-11-8-7-9-12-22/h7-16,20-21,32-34,37-39,42-44,46-47H,6,17-18H2,1-5H3/t20-,21-,32+,33-,34+,37+,38+,39-,42?,43-,44+/m1/s1
SMILES Code
O=C(OC1=C(C2=O)C(C3=C(O2)C=CC(C)=C3C4=O)=C(O4)C5=C(O[C@H]6[C@H](O[C@@H]7[C@H](O)[C@@H](OC)[C@@H](O)[C@@H](C)O7)[C@](OC(C8=CC=CC=C8)O9)([H])[C@]9([H])[C@@H](C)O6)C=CC=C15)CCOCC
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
828.82
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Portugal J. Chartreusin, elsamicin A and related anti-cancer antibiotics. Curr Med Chem Anticancer Agents. 2003 Nov;3(6):411-20. doi: 10.2174/1568011033482215. PMID: 14529449.
2: Asai G, Yamamoto N, Toi M, Shin E, Nishiyama K, Sekine T, Nomura Y, Takashima S, Kimura M, Tominaga T. Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer. Cancer Chemother Pharmacol. 2002 Jun;49(6):468-72. doi: 10.1007/s00280-002-0455-1. Epub 2002 Apr 9. PMID: 12107551.
3: Tashiro T, Kon K, Yamamoto M, Yamada N, Tsuruo T, Tsukagoshi S. Antitumor effects of IST-622, a novel synthetic derivative of chartreusin, against murine and human tumor lines following oral administration. Cancer Chemother Pharmacol. 1994;34(4):287-92. doi: 10.1007/BF00686034. PMID: 8033294.
4: Hino M, Niitani H. [DNA topoisomerase inhibitor]. Nihon Rinsho. 1993 Dec;51(12):3291-300. Japanese. PMID: 8283648.
5: Furue H. [Topoisomerase inhibitors developing in Japan]. Gan To Kagaku Ryoho. 1993 Jan;20(1):42-9. Japanese. PMID: 8422186.
6: Sugiura T, Ariyoshi Y. [DNA topoisomerase inhibitor]. Gan To Kagaku Ryoho. 1992 Nov;19(13):2140-5. Japanese. PMID: 1332623.
